Aytu BioPharma Statistics

Total Valuation

Aytu BioPharma has a market cap or net worth of $17.68 million. The enterprise value is $22.03 million.

Market Cap	17.68M
Enterprise Value	22.03M

Important Dates

The last earnings date was Wednesday, May 14, 2025, after market close.

Earnings Date	May 14, 2025
Ex-Dividend Date	n/a

Share Statistics

Aytu BioPharma has 8.98 million shares outstanding. The number of shares has increased by 52.64% in one year.

Current Share Class	8.98M
Shares Outstanding	8.98M
Shares Change (YoY)	+52.64%
Shares Change (QoQ)	-3.31%
Owned by Insiders (%)	8.50%
Owned by Institutions (%)	3.63%
Float	6.66M

Valuation Ratios

The trailing PE ratio is 10.79 and the forward PE ratio is 8.47.

PE Ratio	10.79
Forward PE	8.47
PS Ratio	0.14
Forward PS	0.88
PB Ratio	0.35
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	13.44
EV / Sales	0.27
EV / EBITDA	3.67
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.03, with a Debt / Equity ratio of 0.65.

Current Ratio	1.03
Quick Ratio	0.76
Debt / Equity	0.65
Debt / EBITDA	2.92
Debt / FCF	n/a
Interest Coverage	-0.30

Financial Efficiency

Return on equity (ROE) is -3.06% and return on invested capital (ROIC) is -1.39%.

Return on Equity (ROE)	-3.06%
Return on Assets (ROA)	-0.59%
Return on Invested Capital (ROIC)	-1.39%
Return on Capital Employed (ROCE)	-2.22%
Revenue Per Employee	$800,578
Profits Per Employee	$16,069
Employee Count	102
Asset Turnover	0.65
Inventory Turnover	2.37

Taxes

In the past 12 months, Aytu BioPharma has paid $467,000 in taxes.

Income Tax	467,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -29.89% in the last 52 weeks. The beta is 0.05, so Aytu BioPharma's price volatility has been lower than the market average.

Beta (5Y)	0.05
52-Week Price Change	-29.89%
50-Day Moving Average	1.53
200-Day Moving Average	1.69
Relative Strength Index (RSI)	57.45
Average Volume (20 Days)	647,309

Short Selling Information

The latest short interest is 416,688, so 4.64% of the outstanding shares have been sold short.

Short Interest	416,688
Short Previous Month	740,353
Short % of Shares Out	4.64%
Short % of Float	6.25%
Short Ratio (days to cover)	0.12

Income Statement

In the last 12 months, Aytu BioPharma had revenue of $81.66 million and earned $1.64 million in profits.

Revenue	81.66M
Gross Profit	52.89M
Operating Income	-1.19M
Pretax Income	-12.61M
Net Income	1.64M
EBITDA	6.00M
EBIT	-1.19M
Earnings Per Share (EPS)	-$0.83

Full Income Statement

Balance Sheet

The company has $18.17 million in cash and $22.52 million in debt, giving a net cash position of -$4.35 million or -$0.48 per share.

Cash & Cash Equivalents	18.17M
Total Debt	22.52M
Net Cash	-4.35M
Net Cash Per Share	-$0.48
Equity (Book Value)	34.90M
Book Value Per Share	5.66
Working Capital	1.81M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$5.53 million and capital expenditures -$211,000, giving a free cash flow of -$5.74 million.

Operating Cash Flow	-5.53M
Capital Expenditures	-211,000
Free Cash Flow	-5.74M
FCF Per Share	-$0.64

Full Cash Flow Statement

Margins

Gross margin is 64.77%, with operating and profit margins of -1.45% and 2.01%.

Gross Margin	64.77%
Operating Margin	-1.45%
Pretax Margin	-0.66%
Profit Margin	2.01%
EBITDA Margin	7.35%
EBIT Margin	-1.45%
FCF Margin	n/a

Dividends & Yields

Aytu BioPharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-52.64%
Shareholder Yield	-52.64%
Earnings Yield	9.27%
FCF Yield	-32.45%

Analyst Forecast

Price Target	n/a
Price Target Difference	n/a
Analyst Consensus	n/a
Analyst Count	n/a
Revenue Growth Forecast (5Y)	9.69%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on January 6, 2023. It was a reverse split with a ratio of 0.05:1.

Last Split Date	Jan 6, 2023
Split Type	Reverse
Split Ratio	0.05:1

Scores

Aytu BioPharma has an Altman Z-Score of -2.8 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-2.8
Piotroski F-Score	3